J. De Castro Carpeño
Hospital Universitario La Paz · 53 works · 250 citations · h-index 7
Top works
- IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
- OA13.05 NADIM Study: Updated Clinical Research and Outcomes
- OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
- LBA53 ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
- OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses
- Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data
- 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain
- [Hemolytic anemia due to cold-reacting antibodies: association with human immunodeficiency virus infection and non-Hodgkin's lymphoma].
- Incidence of vascular thromboembolism events in cancer patients receiving immunotherapy: A single institution experience
- Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
- P1.04-16 Early Antibiotic Use Affects the Efficacy of First Line Immunotherapy in Lung Cancer Patients but Route of Administration Seems to be Decisive
- 360P ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
- 9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)
- LBA12 Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study
- P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients
- Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
- MA01.08 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial)
- 1364TiP Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy
- 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)
- 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy